PRELIMINARY PROGRAMME



9th International Meeting on Rare Disorders of the RAS-MAPK Pathway

A workshop preceding the ESHG conference in Berlin, 2024

Scientific Board: Marco Tartaglia, Alain Verloes, Emma Burkitt-Wright, Martin Zenker

Contacts: marco.tartaglia@opbg.net, martin.zenker@med.ovgu.de,

Organized by: ERN-ITHACA

Date: Friday, May 31, 2024 – Saturday, June 01, 2024

Registration limit: 120 participants

Location: Novotel Berlin am Tiergarten, Str. des 17 Juni 106-108, 10623 Berlin, Germany

PRELIMINARY PROGRAMME

Pre-Programme - *Day 1 (Friday, May 31)*

8^{15} Registration

9^{00} **RASopathies nosology consensus meeting:**
To develop a nosological framework for RASopathies consented by medical experts and stakeholders
(nosology expert panel and interested participants of main meeting)
Chairs: Emma Burkitt-Wright, Bruce Gelb, Marco Tartaglia, Alain Verloes, Martin Zenker

Topics/questions: What is a useful definition for the term RASopathies? How should these disorders be classified? What are the major disease categories? Which diseases should be included/excluded? How should diseases be named?

Expected result: A RASopathy nosology to be published after the meeting

9^{00} Introductory remarks
Martin Zenker

9^{15} Short statements by medical experts and patient advocacy representatives

Noonan syndrome: Michael Patton – Angelo Petroni/Michela Salin (15 min)

NSML: Bruce Gelb (15 min)

NSLH: Laura Mazzanti – Dagmar Tiemens (15 min)

CBL syndrome: Hélène Cavé (15 min)

CFCS: Giuseppe Zampino/Chiara Leoni (15 min)

Costello syndrome: Yoko Aoki (15 min)

NF1 + Legius syndrome: Hilde Brems (15 min)

SYNGAP1: Kirsten Eschermann - Verena Schmeder (15 min)

RASA1 and vascular mosaic RASopathies: Friedrich Kapp – Ruth Kerner (15 min)

Mosaic RASopathies: Alessandro Mussa (15 min)

other RASopathies / related conditions (MAPK1, ERF, RSK2, CDC42, phenocopies): Marco Tartaglia (15 min)

Additional panelists: Emma Burkitt-Wright, Alain Verloes, Christian Kratz (present); Miikka Vikkula, Veronica Kinsler, Karen Gripp (not available for the meeting but for further discussions after the meeting)

12^{00} Discussion
All panel members and participants

12^{30} Lunch Break

Programme - *Day 1 (Friday, May 31)*: Main Part of the meeting

13^{00} Registration

13^{45} Welcome addresses

14^{00} **First Session: Hematology / Oncology**
Chair: Christian Kratz and TBD

14^{00} The nature of myeloproliferative disease in RASopathies (20 min incl. discussion)
Hélène Cavé

14^{20} Brain tumors in RASopathies (20 min incl. discussion)
Pablo Hernáiz Driever

14^{40} Solid tumours in RASopathies: unveiling high-risk genetic variants in a large monocentric cohort through an updated genotype-phenotype analysis (15 min incl. discussion)
Valentina Trevisan

PRELIMINARY PROGRAMME

15^{00} Importance of SPRED1 in cutaneous melanoma (15 min incl. discussion)
Charlotte Carton

15^{15} Modelling lymphoblastic leukemia in children with LZTR1 germline variants using fly avatars for Rasopathy detection (15 min incl. discussion)
Tobias Reiff

15^{30} Coffee Break

16^{00} **Second Session: New insights on molecular players & circuits**
Chair: Marco Tartaglia and Reza Ahmadian

16^{00} SPREDs - Inhibitors of the Ras-MAPK Pathway or Promoters of its Inactivation? (20 min incl. discussion)
Kai Schuh

16^{20} Mechanisms of RIT1 variants in RASopathies (20 min incl. discussion)
Pau Castel

16^{40} Structure and regulation of BRAF: Insights into mechanisms of activation by RASopathy mutations (20 min incl. discussion) **Michael J Eck**

17^{00} Phenotypic heterogeneity associated with *YWHAZ* mutations (20 min incl. discussion)
Marco Tartaglia

17^{20} Shp2 is essential for lymphangiogenesis during zebrafish development (15 min incl. discussion)
Daniëlle Woutersen

17^{35} Diverse behavior of *CDC42* missense mutations cause severe neurodevelopmental conditions (15 min incl. discussion)
Simona Coppola

18^{00} Dinner Buffet

20^{00} **Late session: Mixed short contributions**
Chair: Alain Verloes and Emma Burkitt-Wright

Loss-of-function variants in ERF are associated with a Noonan syndrome-like phenotype with or without craniosynostosis (15 min incl. discussion) **Maria Lisa Dentici**

Recurrence risk in RASopathies (15 min incl. discussion) **Anne Goriely**

Congenital pulmonary airway malformations – a new class of mosaic RASopathies (15 min incl. discussion) **Christian Kratz**

Gastrointestinal pain and microbiome profiling in Costello syndrome (15 min incl. discussion)
Chiara Leoni

High energy expenditure in NS context is associated with increased leptin sensitivity (15 min incl. discussion) **Céline Saint-Laurent**

Autophagosomal dysfunction elicits neurodegenerative tauopathy in biallelic SPRED2 loss-of-function mouse models (15 min incl. discussion) **Sina Gredy**

Roles of senescence and inflammation in frailty associated phenotype in Noonan Syndrome (15 min incl. discussion) **Laurène Mazeyrie**

RASopathies and lymphatic malformation (15 min incl. discussion) **Yoko Aoki**

NF1 pleiotropic phenotype explained by rare variants (15 min incl. discussion) **Giulia Casamassima**

PRELIMINARY PROGRAMME

Preliminary Programme - *Day 2 (Saturday, June 01)*

9^{00}	**Fourth Session: Cardiovascular** **Chair: Cordula Wolf and TBD**
9^{00}	Sudden cardiac death in childhood RASopathy-associated hypertrophic cardiomyopathy (20 min incl. discussion) **Olga Boleti**
9^{20}	Differentiating primary sarcomeric hypertrophic cardiomyopathy from RASopathic cardiomyopathy (20 min incl. discussion) **Cordula Wolf**
9^{40}	Specific RIT1 indels are associated with arteriovenous malformations (20 min incl. discussion) **Friedrich Kapp**
10^{00}	The RAF1:c.770C>T pathogenic variant is associated with a severe Noonan syndrome phenotype with hypertrophic cardiomyopathy and high mortality (15 min incl. discussion) **Andrea Gazzin**
10^{15}	Modeling LZTR1-related cardiac hypertrophy (15 min incl. discussion) **Lukas Cyganek**
10^{30}	Coffee break
11^{00}	**Fifth Session: Neuropsychology** **Chair: Anna Fejtova and Yves Sznajer**
11^{00}	Epilepsy in RASopathies – a comparison between CFC syndrome and SYNGAP1-related encephalopathy (20 min incl. discussion) **Kirsten Eschermann and Lorenz Kiwull**
11^{20}	Impacts of dysregulated RAS-MAPK signalling on functional development of nervous system (20 min incl. discussion) **Anna Fejtova**
11^{40}	Treatment of refractory epilepsy with MEK inhibitor in patients with a RASopathy (20 min incl. discussion) **Gianluca D'Onofrio**
12^{00}	Finding and treating hidden RASopathies among Drosophila models with habituation deficits (15 min incl. discussion) **Boyd van Reijmersdal**
12^{15}	Pathogenesis of cognitive and neurofunctioning impairments in Noonan syndrome patients: the potential role of RAS/MAPK signaling pathway gene disturbances (15 min incl. discussion) **Natalia Braun-Walicka**
12^{30}	Closing remarks

13^{30}	**NSEuroNet – Researchers Meeting** (NSEuroNet partners and external collaborators only)
15^{00}	**Chair: Marco Tartaglia**

Supported by:

Funded by DFG Deutsche Forschungsgemeinschaft German Research Foundation

PRELIMINARY PROGRAMME

Speakers and Chairpersons:

Yoko Aoki, MD, PhD, Department of Medical Genetics, Tohoku University School of Medicine, Sendai, Japan

Hilde Brems, MD, PhD, Department of Human Genetics, University of Leuven, Leuven, Belgium

Olga Boleti, Centre for Paediatric Inherited and Rare Cardiovascular Disease, University College London and Great Ormond Street Hospital, London WC1N 1DZ, UK

Natalia Braun-Walicka, MD, PhD, The Department of Medical Genetics, Institute of Mother and Child, 01-211 Warsaw, Poland

Emma Burkitt-Wright, MD, Manchester Centre for Genomic Medicine, Manchester University NHS Foundation Trust and University of Manchester, Manchester, UK

Charlotte Carton, KU Leuven, Laboratory for Neurofibromatosis Research, Department of Human Genetics, Belgium

Giulia Casamassima, Medical Genetics & Med Biotech Hub and Competence Centre, Department of Medical Biotechnologies, University of Siena, Siena, Italy

Pau Castel, PhD, Department of Biochemistry and Molecular Pharmacology, New York University Grossman School of Medicine, New York, NY 10016, USA

Hélène Cavé, PhD, INSERM UMR_S1131, Institut de Recherche Saint-Louis, Université de Paris & Assistance Publique des Hôpitaux de Paris AP-HP, Hôpital Robert Debré, Département de Génétique, Paris, France

Simona Coppola, PhD, Istituto Superiore di Sanità, Rome, Italy

Lukas Cyganek, PhD, Stem Cell Unit, Clinic for Cardiology and Pneumology, University Medical Center Göttingen & DZHK (German Center for Cardiovascular Research), partner site Göttingen, 37075 Göttingen, Germany

Maria Lisa Dentici, MD, Rare Diseases and Medical Genetics, Ospedale Pediatrico Bambino Gesù, IRCCS, 00146 Rome, Italy

Michael J Eck, PhD, Department of Cancer Biology, Dana-Farber Cancer Institute & Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, 02115, USA.

Kirsten Eschermann, MD, Clinic for Neuropediatrics and Neurological Rehabilitation, Epilepsy Center for Children and Adolescents, Schön Klinik Vogtareuth, Vogtareuth, Germany & Research Institute for Rehabilitation, Transition and Palliation, PMU Salzburg, Austria

Anna Fejtova, PhD, Department of Psychiatry and Psychotherapy, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany

Andrea Gazzin, MD, Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center & Department of Public Health and Pediatrics, University of Turin & Clinical Pediatric Genetics Unit, Regina Margherita Children's Hospital, Turin, Italy

Bruce D. Gelb, MD, PhD, Mindich Child Health and Development Institute, Icahn School of Medicine at Mt. Sinai, New York, NY, USA

Anne Goriely, PhD, MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, UK

Sina Gredy, PhD, Institute of Physiology I, University Wuerzburg, Roentgenring 9, 97070 Wuerzburg, Germany

Pablo Hernáiz Driever, MD, Department of Pediatric Oncology and Hematology, Charité - Universitätsmedizin Berlin, Berlin, Germany

Friedrich Kapp, MD, Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany

Lorenz Kiwull, MD, Clinic for Neuropediatrics and Neurological Rehabilitation, Epilepsy Center for Children and Adolescents, Schön Klinik Vogtareuth, Vogtareuth, Germany & Research Institute for Rehabilitation, Transition and Palliation, PMU Salzburg, Austria

Christian Kratz, MD, Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany

Chiara Leoni, MD, Centre for Rare Diseases and Birth Defects, Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy

Laurène Mazeyrie, PhD, RESTORE Research Center, Université de Toulouse, Institut National de La Santé Et de La Recherche Médicale 1301, Centre National de La Recherche Scientifique 5070 Toulouse, France

Laura Mazzanti, MD, Rare Disease Unit, Department of Pediatrics, St. Orsola-Malpighi Hospital, Bologna, Italy

Gianluca D'Onofrio, MD, Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa, Genoa, Italy & Division of Pediatric Neurology, Department of Neurosciences, CHU Sainte-Justine, Montreal, QC, Canada

Michael Patton, MD, St. Georges University of London, UK

Tobias Reiff, PhD, Institute of Genetics, Department of Biology, The Faculty of Mathematics and Natural Sciences, Heinrich Heine University Düsseldorf, Düsseldorf, Germany

Céline Saint-Laurent, PhD, RESTORE Research Center, Université de Toulouse, INSERM 1301, CNRS 5070, EFS, ENVT, Toulouse, France

Verena Schmeder, President of SYNGAP Familienhilfe, Germany & Patient Board Officer of the EURAS consortium

Lisa Schoyer, MFA, President of RASopathiesNET, 244 Taos Road, Altadena, CA, USA

Kai Schuh, PhD, Institute of Physiology I, University Wuerzburg, Roentgenring 9, 97070 Wuerzburg, Germany

Marco Tartaglia, PhD, Molecular Genetics and Functional Genomics, Ospedale Pediatrico Bambino Gesù, Rome, Italy

Dagmar Tiemens, MD: Department of Pediatrics, Radboud Institute for Health Sciences, Amalia Children's Hospital, Radboud University Medical Center, Nijmegen, The Netherlands

Valentina Trevisan, MD, Centre for Rare Diseases and Birth Defects, Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario “A. Gemelli” IRCCS; and Genomic Medicine, Department of Life Sciences and Public Health, Catholic University of the Sacred Heart, Rome, Italy

Boyd van Reijmersdal, Radboud University Medical Center, Nijmegen & Donders Institute for Brain, Cognition and Behaviour Nijmegen, the Netherlands

Alain Verloes, MD, Department of Genetics, Robert Debré University Hospital, APHP, Paris, France

Cordula Wolf, MD, Department of Congenital Heart Disease and Pediatric Cardiology, German Heart Center Munich, Technical University of Munich, Munich, Germany.

Daniëlle Woutersen, Hubrecht Institute-KNAW and University Medical Center Utrecht, Utrecht, The Netherlands

Giuseppe Zampino, MD, Centre for Rare Diseases and Birth Defects, Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario "A. Gemelli" IRCCS & Department of Life Sciences and Public Health, Catholic University of the Sacred Heart, 00168 Rome, Italy

Martin Zenker, MD, Institute of Human Genetics**,** University Hospital of Magdeburg, 39120 Magdeburg, Germany

Patient Advocacy Representatives (to be completed):

Ruth Kerner, Bundesverband Angeborene Gefäßfehlbildungen e.V., Germany

Angelo Petroni, Angeli Noonan, Associazione Italiana Sindrome di Noonan, Italy

Michela Salin, Angeli Noonan, Associazione Italiana Sindrome di Noonan, Italy

Verena Schmeder, SYNGAP Elternhilfe e.V., Germany